Sanj K. Patel - 16 Mar 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: Chairman & CEO, Director
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact for Sanj K. Patel
Issuer symbol: KNSA
Transactions as of: 16 Mar 2022
Net transactions value: -$19,470
Form type: 4
Filing time: 18 Mar 2022, 16:38:45 UTC
Previous filing: 07 Sep 2021
Next filing: 23 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+6,569			6,569	16 Mar 2022	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$19,470	-1,922	-29%	$10.13	4,647	16 Mar 2022	Direct
holding	KNSA	Class A Common Share						83,336	16 Mar 2022	Held by The Anglia 2013 Revocable Trust, u/d/t August 15,2013
holding	KNSA	Class A Common Share						109,795	16 Mar 2022	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-6,569	-25%	$0.000000	19,707	16 Mar 2022	Class A Common Share	6,569		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.